Geopolitics Alpha

8-K - Neumora Therapeutics, Inc. (0001885522) (Filer)

Published . Updated .

Key takeaways

  • 8-K - Neumora Therapeutics filed an 8-K with the SEC on Nov 16 (a notice of a material company event).
  • Exposed: NMRA
  • Market reaction: price tracking starts with the next trading session.

Market Call

Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.

Get these market calls by email

The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.

Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.

GEOPOLITICS ALPHA8-K - Neumora Therapeutics, Inc.(0001885522) (Filer)NMRAGEOPOLITICS ALPHA

8-K - Neumora Therapeutics filed an 8-K with the SEC on Nov 16 (a notice of a material company event).

Directly affected

  • NMRA Neumora Therapeutics-7.0% 12d

    Named in this report.

Indirectly affected

  • XLV Health Care Select Sector SPDR

    Health Care Select Sector SPDR holds the health sector that Neumora Therapeutics belongs to, so it often moves with news about it.

  • AMGN Amgen+15.9% 30d

    Amgen is a peer of Neumora Therapeutics in biological products, (no diagnostic substances); rivals often move on the same news.

  • GILD Gilead Sciences+16.4% 30d

    Gilead Sciences is a peer of Neumora Therapeutics in biological products, (no diagnostic substances); rivals often move on the same news.

  • MRNA Moderna+22.4% 30d

    Moderna is a peer of Neumora Therapeutics in biological products, (no diagnostic substances); rivals often move on the same news.

  • ARGX argenx SE-11.9% 9d

    argenx SE is a peer of Neumora Therapeutics in biological products, (no diagnostic substances); rivals often move on the same news.

  • RVMD Revolution Medicines

    Revolution Medicines is a peer of Neumora Therapeutics in biological products, (no diagnostic substances); rivals often move on the same news.

Price reaction, T-5 to T+3

TickerT-5T-3T-1T0T+1T+2T+3
NMRA+13.57%+9.58%baseafter closeafter closeafter closeafter close
XLV-0.28%+0.04%baseafter closeafter closeafter closeafter close
AMGN-0.08%+0.56%baseafter closeafter closeafter closeafter close
GILD+0.80%+0.98%baseafter closeafter closeafter closeafter close
MRNA+20.51%+11.41%baseafter closeafter closeafter closeafter close
ARGX+0.34%+1.85%baseafter closeafter closeafter closeafter close
RVMD+16.24%+4.86%baseafter closeafter closeafter closeafter close

Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.

Filed: 2026-11-16 AccNo: 0001193125-26-462165 Size: 355 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

Source: sec-edgar

Price since this story was published: Neumora Therapeutics (NMRA)

CompanyWhenMoveStatus
AMGNthree days earlier+0.56%final price
AMGNfive days earlier-0.08%final price
ARGXthree days earlier+1.85%final price
ARGXfive days earlier+0.34%final price
GILDthree days earlier+0.98%final price
GILDfive days earlier+0.80%final price
MRNAthree days earlier+11.41%final price
MRNAfive days earlier+20.51%final price
Neumora Therapeutics (NMRA)three days earlier+9.58%final price
Neumora Therapeutics (NMRA)five days earlier+13.57%final price
RVMDthree days earlier+4.86%final price
RVMDfive days earlier+16.24%final price
XLVthree days earlier+0.04%final price
XLVfive days earlier-0.28%final price

Congressional trades in the stocks in this story

Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).

Who gains and who loses around Neumora Therapeutics (NMRA)

Companies tied to this story

  • NMRA Neumora Therapeutics

    In “8-K - Neumora Therapeutics, Inc. (0001885522) (Filer),” Neumora Therapeutics (NMRA) is linked, with no stored direction, high confidence. Reason on file: SEC 8-K filing -> direct issuer disclosure -> NMRA

How “8-K - Neumora Therapeutics, Inc. (0001885522) (Filer)” reaches Neumora Therapeutics (NMRA)

The 16 Nov 2026 story “8-K - Neumora Therapeutics, Inc. (0001885522) (Filer)” names Neumora Therapeutics (NMRA) because of this story.

For Neumora Therapeutics (NMRA), the reason on file says SEC 8-K filing -> direct issuer disclosure -> NMRA

Dates and price levels for Neumora Therapeutics (NMRA)

NMRA traded between 0.35 and 0.64 across 12 sessions. The latest close on file is 0.44.

A simple score for Neumora Therapeutics (NMRA)

14 out of 100

“8-K - Neumora Therapeutics, Inc. (0001885522) (Filer)” scores 14 out of 100. The score uses 1 sources, and 1 linked companies.